Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Becton Dickinson (NY: BDX )

240.35 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 198
Open 240.35
Bid (Size) 237.64 (1)
Ask (Size) 242.27 (1)
Prev. Close 240.35
Today's Range 240.35 - 240.35
52wk Range 229.40 - 287.32
Shares Outstanding 287,190,180
Dividend Yield 1.51%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Becton & Dickinson 'Is Well On Its Way To Achieving 2025 Commitments,' Analyst Optimistic On Outlook
BD reports Q2 sales of $5.04 billion, up 4.6% Y/Y. BD Medical, Life Sciences, and Interventional segments show growth. Guidance was raised for 2024 sales, and EPS was adjusted. William Blair rates BDX... 
Via Benzinga
BDX Stock Earnings: Becton, Dickinson Beats EPS, Beats Revenue for Q2 2024
BDX stock results show that Becton, Dickinson beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-2.07%
-2.07%
1 Month
-0.28%
-0.28%
3 Month
-0.83%
-0.83%
6 Month
-6.08%
-6.08%
1 Year
-8.82%
-8.82%

More News

Read More
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Via MarketBeat
Looking Into Becton Dickinson's Recent Short Interest
Via Benzinga
How Much Will $10k Invested in These Dividend Aristocrats Grow to by 2025?
Via InvestorPlace
Peering Into Becton Dickinson's Recent Short Interest
Via Benzinga
Peering Into Becton Dickinson's Recent Short Interest
Via Benzinga
Becton Dickinson Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Rich Returns at a Discount: 3 Dividend Aristocrats Trading at 52-Week Lows
Via InvestorPlace
AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Should You Buy Solventum (SOLV) Stock After the 3M Spinoff?
Via InvestorPlace
Jim Cramer Says Don't Sell This Beauty Brand, Believes KKR And Blackstone 'Can Make More Money'
Via Benzinga
Becton, Dickinson And Co. Dividend Stock Analysis
Via Talk Markets
Earnings Preview For Becton, Dickinson
Via Benzinga
FDA Probe On China-Made Syringes: Becton Dickinson Boosts US Syringe Output Following Concerns
Via Benzinga
Exposures Product Safety
10 Big-Name Stocks Near 52-Week Lows: Are They A Buy?
Via Talk Markets
7 Robotic Surgery Stocks to Buy for the Future of Healthcare
Via InvestorPlace
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
Via The Motley Fool
3 Stocks to Buy at 52-Week Lows: March 4 Edition
Via InvestorPlace
Get Paid While You Wait: 7 Dividend Aristocrats to Buy Now
Via InvestorPlace
Medical Device Maker Becton Dickinson's Q1 Earnings: Here's Why This Analyst Is Bullish On Long-Term Prospects
Via Benzinga
Biotech And Medtech Portfolio Notes On A Fed Day
Via Talk Markets
Topics Economy
Exposures Interest Rates
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Via Benzinga
Earnings Scheduled For February 1, 2024
Via Benzinga
Jim Cramer Says Hold Onto This Biotech Stock: 'I Don't Understand Why It's So Inexpensive'
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.